Health & Wellness

09/30/2026 · Columbus

Eli Lilly's EloraTZP Shows Greater Weight and A1C Reduction in Phase 2b Trial

Eli Lilly's experimental drug EloraTZP, a combination of eloralintide and tirzepatide, demonstrated superior weight loss and A1C reduction compared to tirzepatide 15 mg in a 48-week Phase 2b study. Participants taking EloraTZP lost significantly more weight and saw greater improvements in their blood sugar levels.

10/01/2026

Read Story

Health

Unvaccinated Lancaster County Resident Dies From Measles

Pennsylvania health officials announced Wednesday the death of an unvaccinated Lancaster County resident who tested positive for measles. This marks the fifth measles-related death reported in the state.

10/01/2026

Health

Dementia Patient Medication Use: A Michigan Case Study

A Michigan woman's case highlights family and guardian choices concerning sedating medications for agitated dementia patients. These medications are used in long-term care facilities. Federal initiatives aim to reduce their application.

09/30/2026

Health

HHS Report on Gender-Affirming Care Draws Scrutiny

A recent report from a federal health agency is prompting discussion regarding established healthcare models for transgender individuals. Critics characterize the report's framing of transgender identity in specific ways.

09/30/2026

Health

Measles Cases Reported in Multiple States, Exposure Sites Include Travel and Public Events

Measles outbreaks have appeared in Pennsylvania, Ohio, and New York. Health officials have identified potential exposure locations, including public transportation and sports events. Individuals planning travel should consult health guidelines.

09/30/2026

Health

Eli Lilly Drug Retatrutide Shows Weight Loss in Type 2 Diabetes Trial

Eli Lilly's experimental drug retatrutide led to notable weight reduction in individuals with Type 2 diabetes, according to new trial results. Participants in the study, published in The Lancet, experienced an average loss of up to 60 pounds.

09/30/2026